PCA3 has an Established Place in the Diagnosis of Prostate Cancer
QUEBEC CITY, March 21, 2013 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR)
is pleased to report that Dr. Harry Rittenhouse spoke about the
clinical utility of the urinary marker PCA3 during the International
Conference on Prostate Cancer Prevention 2013 with Consensus Conference
on Chemoprevention of Prostate Cancer held during the 28th annual European Association of Urology (EAU) congress held in Milan
from March 15-19th.
One of the goals of this day-long special session during the EAU
congress was to discuss current management approaches to prostate
cancer screening and hopefully come up with some consensus statements
in early detection and prognostic biomarkers to predict high grade
disease and the most appropriate clinical preventions. One of the
session chairmen, Professor Powel Brown of M.D. Anderson Cancer Center
in Houston, Texas, shared his hopes to see a strong message on the use
of biomarkers for prognostic stratification of prostate cancer into low
and high risk disease. For Dr. Jack A. Schalken, Professor of
experimental urology at the Radboud University Nijmegen Medical Center
(The Netherlands), there is no doubt that "PCA3 has an established
place in the diagnosis of prostate cancer and is now also considered
for follow-up use in chemoprevention studies".
In a separate thematic session where prostate cancer experts from both
sides of the Atlantic discussed current work on candidate tumor markers
for prostate cancer and the prospects for these biomarkers to serve as
possible replacements for PSA-based diagnosis, presentations were given
by Dr. Jack Groskopf (Hologic Gen-Probe, USA) who discussed urinary
markers PCA3 and TMPRSS2-ERG, and Dr. Monique Roobol (Erasmus
University Medical Center, The Netherlands) who provided insights on
studies that examine reducing unnecessary biopsies for suspicion of
The Annual EAU Congress is Europe's largest urology event and serves as
a platform for the international urological community to share the
latest and the most relevant knowledge with medical experts practicing
across the board.
DiagnoCure (TSX: CUR) is a life sciences corporation that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license agreement to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic
Gen-Probe, for the development and commercialization of a prostate
cancer test using PCA3, DiagnoCure's proprietary molecular biomarker.
Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe
under CE mark and is approved for commercialization in Canada and the
United States. For more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward‐looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward‐looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward‐looking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE: DiagnoCure inc.
For further information:
Chief Financial Officer
Coordinator, Administration and Communications